A method for the treatment of diseases and / or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition. Claim 1: A compound characterized in that it has formula (1) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a salt acceptable for pharmaceutical use or a prodrug thereof, where: X is N, CH or ÅN-O ²⁰ ；；D-ring is 5-member heteroaromatic ring or 5-member heteroaromatic ring； L is a link, - (Cr3 r830808) 75844；- (CR R) -O-- (CR R) -NH- o - (CR R) -S (3DO) -R is a fusion tricycle or an isobutylene fusion tricycle. In this case, R can be replaced by one, two, three, four or five r831222；Each R1 R1 is independent of H, deuterium, F, Cl, Br, l, hydroxi, amine, nitro, cyanogen, asphalt, tar, halogen, halogen alcoxi, cyclopentadiene, isopropene, alquenilo, tar, lease, alcoxi, alcoxi or isopropene； R2 is h, deuterium, F, Cl, Br, I, hydroxi, amino, nitro, cyanogen, asphalt, tar, halogen, halogen, alcoxi l o, cyclohexane, cyclohexane, a. Each type of R3 and r83088 are independent h, deuterium, c832183-83331；F, Cₗ,B6911,ₗₒ ₕₐₗₒₐₗqᵘⁱₗₒ C₁₋₄a. Each r831222 is independent of H, deuterium, F, Cl, Br, I, hydroxi, nitro, amino, aminoal quilo, rent, asphalt, hydroxy, haloalkyl, halogenated alcoxi, cyclopentadiene, cyclomethoxy, cyclopentadienyl, cyclopentadienyl, tar, arilo halo alternatives, arilalquilo, oxo (= O),-L -C (3DO) OR-L -S (3DO) R-O-L -C (3DO) OR-O-L -S (3DO) R-C (3DO) NR R-C (3DO) N (R) S (3DO) R-C (3DNR) NR R-C (3DO) N (R) -L -S (3DO) OR-C (3DO) N (R) C (3DO) OR-C (3DO) N (R) -L -C (3DO) ORCyanogen, isopropene or isopropene； or 2r831222,Combined with the same C atom, they independently and optionally form cyclopropyl or acylpropyl； or two r831222,c. With the adjacent C atom, it forms cyclopentyl, isopropyl, isopropyl or isopropyl independently and optionally； r831222 is replaced by one or more r8313 independently and optionally；a. Each r83099 does not contain h, deuterium, ta
